Annual Cash & Cash Equivalents
$1.29 M
+$1.07 M+498.47%
December 31, 2023
Summary
- As of February 26, 2025, PTIX annual cash & cash equivalents is $1.29 million, with the most recent change of +$1.07 million (+498.47%) on December 31, 2023.
- During the last 3 years, PTIX annual cash & cash equivalents has risen by +$616.80 thousand (+91.91%).
- PTIX annual cash & cash equivalents is now -93.69% below its all-time high of $20.41 million, reached on December 31, 2008.
Performance
PTIX Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$1.06 M
+$131.20 K+14.19%
September 30, 2024
Summary
- As of February 26, 2025, PTIX quarterly cash and cash equivalents is $1.06 million, with the most recent change of +$131.20 thousand (+14.19%) on September 30, 2024.
- Over the past year, PTIX quarterly cash and cash equivalents has stayed the same.
- PTIX quarterly cash and cash equivalents is now -95.34% below its all-time high of $22.65 million, reached on March 31, 2009.
Performance
PTIX Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
PTIX Cash And Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +498.5% | 0.0% |
| 3 y3 years | +91.9% | 0.0% |
| 5 y5 years | +255.3% | 0.0% |
PTIX Cash And Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +498.5% | -18.0% | +662.3% |
| 5 y | 5-year | at high | +498.5% | -91.2% | +662.3% |
| alltime | all time | -93.7% | -100.0% | -95.3% | -100.0% |
Protagenic Therapeutics Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $1.06 M(+14.2%) |
| Jun 2024 | - | $924.60 K(+11.2%) |
| Mar 2024 | - | $831.80 K(-35.4%) |
| Dec 2023 | $1.29 M(+498.5%) | $1.29 M(+740.1%) |
| Sep 2023 | - | $153.30 K(-30.1%) |
| Jun 2023 | - | $219.40 K(+58.4%) |
| Mar 2023 | - | $138.50 K(-35.6%) |
| Dec 2022 | $215.20 K(-60.2%) | $215.20 K(+35.9%) |
| Sep 2022 | - | $158.30 K(-53.3%) |
| Jun 2022 | - | $338.70 K(-29.8%) |
| Mar 2022 | - | $482.20 K(-10.9%) |
| Dec 2021 | $541.20 K(-19.4%) | $541.20 K(+17.6%) |
| Sep 2021 | - | $460.10 K(-96.1%) |
| Jun 2021 | - | $11.93 M(+6124.8%) |
| Mar 2021 | - | $191.70 K(-71.4%) |
| Dec 2020 | $671.10 K(-16.0%) | $671.10 K(-32.1%) |
| Sep 2020 | - | $988.60 K(-16.3%) |
| Jun 2020 | - | $1.18 M(+56.7%) |
| Mar 2020 | - | $754.00 K(-5.6%) |
| Dec 2019 | $798.60 K(+120.3%) | $798.60 K(+187.9%) |
| Sep 2019 | - | $277.40 K(-18.3%) |
| Jun 2019 | - | $339.50 K(-19.0%) |
| Mar 2019 | - | $419.30 K(+15.7%) |
| Dec 2018 | $362.50 K(-9.3%) | $362.50 K(-16.1%) |
| Sep 2018 | - | $431.90 K(+83.0%) |
| Jun 2018 | - | $236.00 K(-31.3%) |
| Mar 2018 | - | $343.30 K(-14.1%) |
| Dec 2017 | $399.70 K(-87.1%) | $399.70 K(-58.0%) |
| Sep 2017 | - | $952.10 K(+51.7%) |
| Jun 2017 | - | $627.80 K(-77.1%) |
| Mar 2017 | - | $2.75 M(-11.5%) |
| Dec 2016 | $3.10 M(+4900.6%) | $3.10 M(-11.1%) |
| Sep 2016 | - | $3.49 M(-7.9%) |
| Jun 2016 | - | $3.79 M(+1.0%) |
| Mar 2016 | - | $3.75 M(>+9900.0%) |
| Dec 2015 | - | $4000.00(-60.0%) |
| Sep 2015 | - | $10.00 K(-83.9%) |
| Jun 2015 | $62.00 K(-38.6%) | $62.00 K(+8.8%) |
| Mar 2015 | - | $57.00 K(-62.0%) |
| Dec 2014 | - | $150.00 K(+35.1%) |
| Sep 2014 | - | $111.00 K(+9.9%) |
| Jun 2014 | $101.00 K(-85.9%) | $101.00 K(-94.9%) |
| Jun 2013 | $717.00 K(-88.7%) | - |
| Sep 2011 | - | $2.00 M(-13.5%) |
| Jun 2011 | - | $2.31 M(+44.1%) |
| Mar 2011 | - | $1.60 M(-74.6%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2010 | $6.32 M(-62.6%) | $6.32 M(+48.7%) |
| Sep 2010 | - | $4.25 M(-41.5%) |
| Jun 2010 | - | $7.27 M(-41.7%) |
| Mar 2010 | - | $12.47 M(-26.2%) |
| Dec 2009 | $16.91 M(-17.1%) | $16.91 M(-3.9%) |
| Sep 2009 | - | $17.59 M(-13.9%) |
| Jun 2009 | - | $20.43 M(-9.8%) |
| Mar 2009 | - | $22.65 M(+11.0%) |
| Dec 2008 | $20.41 M(+168.1%) | $20.41 M(-6.8%) |
| Sep 2008 | - | $21.89 M(+27.6%) |
| Jun 2008 | - | $17.15 M(+1.3%) |
| Mar 2008 | - | $16.93 M(+122.4%) |
| Dec 2007 | $7.61 M(+1299.3%) | $7.61 M(-41.4%) |
| Sep 2007 | - | $12.99 M(-7.1%) |
| Jun 2007 | - | $13.99 M(-21.1%) |
| Mar 2007 | - | $17.72 M(>+9900.0%) |
| Dec 2006 | $544.00 K(>+9900.0%) | - |
| Oct 2006 | - | $900.00(-55.0%) |
| Jul 2006 | - | $2000.00(-53.5%) |
| Jul 2006 | $2000.00(-100.0%) | - |
| Apr 2006 | - | $4300.00(+2.4%) |
| Jan 2006 | - | $4200.00(-82.5%) |
| Jul 2004 | $4.53 M(>+9900.0%) | - |
| Apr 2003 | - | $24.00 K(-22.6%) |
| Jan 2003 | - | $31.00 K(+6.9%) |
| Oct 2002 | - | $29.00 K(+163.6%) |
| Jul 2002 | $11.00 K(-31.3%) | $11.00 K(-62.1%) |
| Apr 2002 | - | $29.00 K(+81.3%) |
| Jan 2002 | - | $16.00 K(-77.8%) |
| Oct 2001 | - | $72.00 K(+350.0%) |
| Jul 2001 | $16.00 K(>+9900.0%) | $16.00 K(-11.1%) |
| Apr 2001 | - | $18.00 K(-67.3%) |
| Jan 2001 | - | $55.00 K(+120.0%) |
| Oct 2000 | - | $25.00 K(>+9900.0%) |
| Jul 2000 | $0.00(-100.0%) | $0.00(-100.0%) |
| Apr 2000 | - | $20.00 K(-28.6%) |
| Jan 2000 | - | $28.00 K(-72.0%) |
| Oct 1999 | - | $100.00 K(-24.8%) |
| Jul 1999 | $133.00 K(+291.2%) | $133.00 K(-55.7%) |
| Apr 1999 | - | $300.00 K(-25.0%) |
| Jan 1999 | - | $400.00 K(+300.0%) |
| Oct 1998 | - | $100.00 K(+194.1%) |
| Jul 1998 | $34.00 K(-88.7%) | $34.00 K(-66.0%) |
| Apr 1998 | - | $100.00 K(-66.7%) |
| Jul 1997 | $300.00 K | $300.00 K(-83.3%) |
| Apr 1997 | - | $1.80 M(0.0%) |
| Jan 1997 | - | $1.80 M |
FAQ
- What is Protagenic Therapeutics annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Protagenic Therapeutics?
- What is Protagenic Therapeutics annual cash & cash equivalents year-on-year change?
- What is Protagenic Therapeutics quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Protagenic Therapeutics?
- What is Protagenic Therapeutics quarterly cash and cash equivalents year-on-year change?
What is Protagenic Therapeutics annual cash & cash equivalents?
The current annual cash & cash equivalents of PTIX is $1.29 M
What is the all time high annual cash & cash equivalents for Protagenic Therapeutics?
Protagenic Therapeutics all-time high annual cash & cash equivalents is $20.41 M
What is Protagenic Therapeutics annual cash & cash equivalents year-on-year change?
Over the past year, PTIX annual cash & cash equivalents has changed by +$1.07 M (+498.47%)
What is Protagenic Therapeutics quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of PTIX is $1.06 M
What is the all time high quarterly cash and cash equivalents for Protagenic Therapeutics?
Protagenic Therapeutics all-time high quarterly cash and cash equivalents is $22.65 M
What is Protagenic Therapeutics quarterly cash and cash equivalents year-on-year change?
Over the past year, PTIX quarterly cash and cash equivalents has changed by $0.00 (0.00%)